Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 17,799 | 18,592 | 15,831 | 24,178 | 31,606 |
| TOTAL | $19,552 | $20,552 | $17,121 | $25,785 | $33,507 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 673 | 733 | 793 | 101 | 108 |
| TOTAL | $673 | $733 | $793 | $101 | $108 |
| Total Assets | $20,225 | $21,285 | $17,914 | $25,886 | $33,615 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,553 | 3,890 | 2,352 | 2,964 | 1,906 |
| Accrued Expenses | 8,980 | 9,058 | 7,236 | 7,864 | 7,629 |
| TOTAL | $11,533 | $13,012 | $9,588 | $10,892 | $9,535 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 51,338 | 40,467 | 30,661 | 30,217 | 30,273 |
| TOTAL | $51,338 | $40,467 | $30,661 | $30,217 | $30,273 |
| Total Liabilities | $62,871 | $53,479 | $40,249 | $41,109 | $39,808 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 59,582 | 59,444 | 59,426 | 59,396 | 59,389 |
| Common Shares | 59 | 59 | 59 | 59 | 59 |
| Retained earnings | -321,094 | -309,567 | -298,868 | -290,287 | -280,610 |
| Other shareholders' equity | 2,233 | 2,233 | 2,233 | 2,233 | 2,250 |
| TOTAL | $-42,646 | $-32,194 | $-22,335 | $-15,223 | $-6,193 |
| Total Liabilities And Equity | $20,225 | $21,285 | $17,914 | $25,886 | $33,615 |